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Abstract 
Background: About 10–15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in 
KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1). The identification of additional mutated genes 
in this rare subset of tumors can have important clinical benefit to identify altered biological pathways and select 
targeted therapies.
Methods: We performed comprehensive genomic profiling (CGP) for coding regions in more than 300 cancer‑
related genes of 186 GISTs to assess for their somatic alterations.
Results: We identified 24 GIST lacking alterations in the canonical KIT/PDGFRA/RAS pathways, including 12 with‑
out SDHx alterations. These 24 patients were mostly adults (96%). The tumors had a 46% rate of nodal metastases. 
These 24 GIST were more commonly mutated at 7 genes: ARID1B, ATR, FGFR1, LTK, SUFU, PARK2 and ZNF217. Two 
tumors harbored FGFR1 gene fusions (FGFR1–HOOK3, FGFR1–TACC1) and one harbored an ETV6–NTRK3 fusion that 
responded to TRK inhibition. In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/
PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1–TACC1 and ETV6–NTRK3 fusions.
Conclusions: Using patient demographics, tumor characteristics, and CGP, we show that GIST lacking alterations 
in canonical genes occur in younger patients, frequently metastasize to lymph nodes, and most contain deleterious 
genomic alterations, including gene fusions involving FGFR1 and NTRK3. If confirmed in larger series, routine test‑
ing for these translocations may be indicated for this subset of GIST. Moreover, these findings can be used to guide 
personalized treatments for patients with GIST.
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Background
Gastrointestinal stromal tumors (GISTs) are the most 
common sarcoma affecting approximately 3500 new 
patients per year in the United States [1]. Approximately 
70–80% of sporadic GISTs are caused by gain-of-func-
tion mutations in KIT (c-KIT, CD117); another 5–10% 
are caused by activating genomic alterations in platelet-
derived growth factor receptor alpha (PDGFRA) [2–4]. 
Even less common are tumors driven by RAS pathway 
gene mutations (e.g., BRAF, KRAS, NF1; 1–3% com-
bined) or mutations/deficiencies in the four succinate 
dehydrogenase (SDH subunits (A, B, C, or D; 3% com-
bined) [2, 3, 5–8].
Given the initial understanding that the majority of 
GISTs were driven by KIT, the application of targeted 
drugs such as imatinib mesylate (Novartis, Basel, Swit-
zerland) allowed GIST to serve as the paradigm for 
cancer genotyping and the development of “matched” 
therapies for solid malignancies. Imatinib and other small 
molecule tyrosine kinase inhibitors have demonstrated 
clear anti-GIST activity by targeting oncogenic KIT and 
PDGFRA mutations, and as a result, these drugs are now 
firmly established in treatment of GIST patients [9].
However, approximately 5–15% of adult GIST patients, 
and most pediatric patients, who tend to be imatinib-
resistant, were initially designated as “wild-type (WT)” 
until other oncogenic mutations were identified. Some 
have termed this subset of patients “quadruple-WT 
(qWT)”, or “quadruple-negative GISTs” because they 
lack oncogenic mutations in any of the aforementioned 
genes [10]. Since the designation of qWT GIST, only one 
study has attempted to define and compare its molecu-
lar profile to other GISTs, reporting the overexpression 
of polycomb target genes (e.g., CDK6, ERG and NTRK2) 
as potential drivers and identifying potential diagnostic 
markers (e.g., CALCRL and COL22A1) [11]. This study 
provided insight into alternative pathways that may be 
involved in GIST oncogenesis; however, this report was 
limited by analyzing only two so-called qWT tumors. 
Beyond this study, there is a lack of reports addressing 
the clinical demographics and molecular characteristics 
of qWT GISTs [10]. Thus, the patient demographics, 
pathological data (i.e., tumor location), and genomic 
profile of qWT GISTs are largely unknown. These defi-
ciencies in our knowledge leave affected patients at a 
disadvantage by not identifying the genetic abnormali-
ties that could be used to diagnose GIST and delay the 
development of novel and potentially beneficial precision 
therapies for qWT GIST.
Given the increasing application of comprehensive 
genetic profiling (CGP) towards personalized medicine 
treatments in oncology, we hypothesized that analyz-
ing demographic data, pathological data, and genomic 
profiles of quadruple-WT GIST would begin to define 
the pathobiology of this largely undefined GIST subtype, 




The Foundation Medicine, Inc. (Cambridge, MA, USA) 
database consists of patients from across the world 
treated in both academic and private practice settings. 
De-identified tumor samples were selected from the data-
base of patients who underwent Foundation One™ anal-
yses in the course of clinical care from October 2012 to 
May 2015, where 186 tumors were categorized as GISTs 
according to pathologists at the diagnosing institutions. 
Demographic and clinicopathologic data were compared 
to population-based data (N = 6112) from the National 
Cancer Institute’s Surveillance, Epidemiology, and End 
Results (SEER) database with histologically-confirmed 
GIST between 2001 and 2011 [1].
Study design
Patient demographic and tumor clinicopathologic data 
included age and sex, primary GIST site, tumor biopsy 
site, and TNM disease stage. We retrospectively ana-
lyzed this prospectively collected data under a Univer-
sity of California, San Diego Institutional Review Board 
approved protocol (#141555X). An experienced patholo-
gist (JSR) centrally re-reviewed hematoxylin and eosin-
stained sections of 29 tumors lacking driver mutations in 
KIT, PDGFRA, or RAS pathway components (BRAF, NF1, 
KRAS, HRAS, NRAS). Additionally, 12 tumors lacked 
driver mutations in SDHx. Five tumors were excluded as 
more consistent with other sarcoma subtypes.
Comprehensive genomic profiling
GIST tumor specimens were taken from either primary 
or secondary tumor biopsies and submitted to a Clini-
cal Laboratory Improvement Act certified, College of 
American Pathologists and New York State accredited 
laboratory, Foundation Medicine, Inc. (FMI), by health-
care providers from various medical institutions. Com-
prehensive genomic profiling (CGP) was performed on 
hybridization-captured, adaptor ligation-based librar-
ies using DNA extracted from four formalin-fixed par-
affin embedded (FFPE) sections cut at 10  µm from the 
tumors. All samples sent for DNA extraction contained 
a minimum of 20% tumor nuclei. The FoundationOne™ 
assay is a next-generation sequencing-based genomic 
assay that utilizes the Illumina HiSeq  2500 instrument 
(Illumina Inc., San Diego, CA, USA) to sequence coding 
regions of more than 182 cancer related genes (includ-
ing SDHx for 109 patients). The number of genes in the 
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FoundationOne™ panel has evolved over time as new 
data on cancer-related genes has been published. But, all 
versions of the assay simultaneously analyze the extracted 
DNA for base substitutions, short insertions and dele-
tions, amplifications and homozygous deletions and gene 
rearrangements as previously described [12].
Genomic analysis
The genomic alterations were identified using Founda-
tion Medicine workflow [12]. To maximize sensitivity in 
heterogeneous GIST specimens, the test was validated to 
detect base substitutions, as well as short insertions and 
deletions at ≥10% mutant allele frequency with ≥99% sen-
sitivity, The genomic alterations were further categorized 
[i.e., known somatic, likely somatic, or variant of unknown 
significance (VUS)] according to Foundation Medicine 
classification [12]. Furthermore, point mutations and small 
indels were annotated for their functional effect on the 
protein (missense, nonsense, frameshift, etc.).
In order to expand our understanding of the potential 
deleterious effect of missense VUSs, we mapped them 
to the dbNSFP database, which pre-computed multi-
ple scores for all possible base substitutions in coding 
regions [13, 14]. VUSs that were predicted deleterious 
by at least 2 out of 4 prediction tools (SIFT, PolyPhen, 
MutationTaster, and/or MutationAssessor) were included 
in further analyses (Additional file 1: Table S1). Any mis-
sense VUS that did not meet this criterion was excluded 
and not reported.
As the FMI sequencing process does not include 
sequencing of a matched normal tissue for germline anal-
ysis, it is possible for predicted-deleterious inherited var-
iants in cancer related genes to be detected and included 
in the reports with somatic variants. Thus, we sought 
to exclude common non-SDH [A-D] and non-NF1 ger-
mline alterations in order to focus on putative somatic 
alterations. The Exome Aggregation Consortium (ExAC) 
Browser (https://exac.broadinstitute.org) provides a relia-
ble registry of all known human germline variation down 
to a minor allele frequency of 10−5 [15]. We were able to 
match 495/1605 (30.8%) of the short variants to the same 
residue, as well as with the same amino-acid substitu-
tion in the ExAC database (version 0.3) using the protein 
annotation. Mutations present in the ExAC database at 
a minor allele frequency greater than 1% (i.e., NOTCH2, 
FANCD2, MAP3K1, MSH3, and ZNF217), indicating 
potential germline variants, were also excluded from 
analysis (Additional file 1: Table S2).
Secondary study population
To confirm our results, we identified 5 additional cases 
of qWT GIST after clinical testing at the Knight Diag-
nostic Laboratory (OHSU Knight Cancer Institute, 
Portland, OR, USA). All of these cases had been previ-
ously screened for mutations in genes known or thought 
to be involved in GIST biology using a custom panel 
including hotspots or entire coding regions of AKT1, 
AKT2, AKT3, ATM, BRAF, CDKN2A, HRAS, KIT, 
KRAS, MAP2K1, NF1, NRAS, PDGFRA, PIK3CA, 
PTEN, PTPN11, SDHA, SDHAF1, SDHAF2, SDHB, 
SDHC, SDHD and TP53. Library preparation, sequenc-
ing, and variant calling were carried out using reagents, 
instruments and software from Thermo Fisher Scientific, 
as previously described [16]. Libraries were amplified by 
emulsion PCR on ion sphere particles (ISPs) using an Ion 
Xpress Template Kit. The templated ISPs were recovered 
from the emulsion, and enriched with MyOne strepta-
vidin C1 Dynabeads. Eight barcoded samples were mul-
tiplexed on an Ion 318 chip and sequenced on a PGM 
sequencer (Ion PGM200 sequencing kit). Torrent Suite 
software version 4.0 was used to parse barcoded reads, to 
align reads to the reference genome, and to generate run 
metrics, including chip loading efficiency and total read 
counts and quality. Variants were identified with Vari-
ant Caller software version 4.0, and target coverage was 
evaluated with Coverage Analysis software version 4.0 
[16]. Amplicon sequencing libraries were prepared from 
20 ng of RNA purified from residual DNA from previous 
clinical testing using the Ion Total RNA-Seq kit (Thermo 
Fisher Scientific) according to the manufacturer’s instruc-
tions. These libraries were subjected to analysis using a 
panel that included primer pairs for 169 known gene 
fusions that involve target genes and 94 fusion partners 
(Additional file 1: Table S3) as previously described [17].
Results
Demographic and clinicopathologic tumor data
The vast majority of tumors (87.1%, 162/186) con-
tained mutations in known or suspected drivers of GIST 
(Table  1). In contrast, we identified 24 (13%) patients 
Table 1 Identification of  quadruple wild-type GIST (qWT) 
Subset in 186 GIST
a Genomic alterations are not mutually exclusive and are potentially germline 
(e.g., NF1 and SDH [ABCD]). Of the 162 non-WT GISTs, 32 tumors had one or 
more genomic alterations in KIT, PDGFRA, NF1, SDH [A-D], BRAF, and/or [KNH] 
RAS
Category Number of patientsa Percent of patients (%)
KIT mutated 129 69
PDGFRA mutated 22 12
NF1 mutated 18 10
SDH [ABCD] mutated 14 8
BRAF mutated 7 4
[KNH] RAS mutated 4 2 
qWT 12 6 
SDH unknown 12 6 
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with WT tumors. This included 12 tumors identified as 
KITWT/PDGFRAWT/BRAFWT/SDHWT/NF1WT/KRASWT/
HRASWT/NRASWT or qWT GIST and 12 tumors identi-
fied as KITWT/PDGFRAWT/BRAFWT/NF1WT/KRASWT/
HRASWT/NRASWT GIST with unknown SDH status.
Demographic and clinicopathologic data for these 24 
patients are provided in Additional file  1: Table  S4. In 
the WT GIST subset, the average age at diagnosis was 
44.4 ± 15.7 (median 45 years old) with equal gender dis-
tribution. The tumor samples were obtained from pri-
mary tumors (N =  15, 62.5%), metastatic sites (N =  6, 
25%), or unknown abdominal sites (N =  3, 12.5%). The 
stomach was the most common primary site (N  =  13, 
54.2%), similar to SEER data (P = 0.23). All patients had 
tumors greater than 2  cm. The WT cohort mainly con-
sisted of tumors that are  >5 and  ≤10  cm (66.7%). An 
additional 8.3% were smaller and 20.8% were larger. Data 
on mitotic index was not available. In addition, the WT 
cohort consisted of 45.8% with lymph node metasta-
ses (N1) and 70.8% with distant metastases (M1). Thus, 
WT GISTs occurred throughout the GI tract, tended to 
be large in size (>5 cm), and frequently had nodal and/or 
distant metastases.
Genomic alterations in GIST
In the 186 GISTs studied, CGP revealed a total of 1385 
unique alterations (1276 short variants, 83 copy number 
alterations and 26 rearrangements) affecting all 186 GIST 
patients (Additional file 1: Figure S1; Table S5). The cohort 
assembled reflects, at the genomic level, the current 
knowledge of sporadic GIST in the U.S. Genomic altera-
tions in the canonical genes affected 162 GIST (referred 
to as non-WT) were not mutually exclusive as has been 
previously reported [18]. Indeed, 32 non-WT tumors 
had two or more genomic alterations in KIT, PDGFRA, 
NF1, SDH [A-D], BRAF, and/or [KNH]RAS (Additional 
file  2: Table  S6). Overall, 129/186 (69%) of GISTs had a 
KIT alteration. Similarly, PDGFRA was the second most 
commonly mutated canonical gene with 22 of 186 (12%) 
cases. Of the subset of 97 non-WT GIST tested for SDH, 
14 (14.4%) had a mutation detected, 6 of them in absence 
of any mutations in KIT, PDGFRA or RAS pathways.
In the 24 tumors designated as WT (i.e., KITWT/PDG-
FRAWT/BRAFWT/SDHWT/UNKNOWN/NF1WT/HRASWT/
NRASWTKRASWT), CGP analyses revealed an average 
of 7.6 ± 3.2 genomic alterations (range: 3–17). Over the 
entire WT cohort, 120 genes are altered; the alterations 
include 120 missense mutations, 19 in-frame indels, 11 
frameshifts, 10 copy number alterations (6 amplifications 
and 4 losses, 6.4%), 5 nonsense mutations, 3 gene fusions, 
3 rearrangements, and 6 unclassified mutations (Fig. 1). 
The affected genes and their respective alterations are 
listed in Additional file 3: Table S7.
There are 39 genes recurrently mutated in the WT 
samples (Fig.  2). The genes most commonly altered 
in WT tumors were LRP1B (N =  6), ARID1B (N =  5), 
and NOTCH1 (N  =  4). Importantly, these genes are 
also recurrently mutated in qWT alone. LRP1B, the 
most frequently mutated gene in qWT GIST, is an LDL 
receptor-related protein involved in hepatic metabo-
lism, tissue remodeling, and cellular migration. Its 
cytoplasmic domain is demonstrated to interact with 
components of the PKC and RAS-MAPK pathways 
[19]. Evidence is mounting that LRP1B may function 
as a broad-spectrum tumor suppressor, with dysfunc-
tion potentially linked to increased tumor invasion and 
chemotherapeutic resistance [20–23]. LRP1B mutations 
may also be associated with upregulation of inflamma-
tory responses, consistent with a growing body of evi-
dence that chronic inflammation predisposes to cancer 
formation [24].
In order to identify potential drivers specific to WT 
GIST, we determined whether the recurrently mutated 
genes were more likely to be mutated in WT than in 
non-WT GIST. We identified 7 genes significantly more 
mutated in WT patients (P < 0.05): LTK, SUFU, ZNF217, 
ARID1B, PARK2, ATR, and FGFR1 (Table 2). The FGFR1 
gene is altered with 1 missense mutation and 2 gene 
fusions including FGFR1–HOOK3 (predicted activat-
ing in-frame fusion of FGFR1 intron 17 and HOOK3 
intron 4) and FGFR1–TACC1 [25] (predicted activating 
in-frame fusion of FGFR1 intron 17 and TACC1 intron 
6) (Fig.  3a). All three FGFR1 alterations identified in 
Fig. 1 Types of Genomic Alterations Detected on Broad Genetic 
Profiling of Wild‑Type GIST. Bar graph demonstrates the types of 
genomic alterations identified in WT GIST as determined by CGP). 
Percentages and total numbers (N) of mutations are indicated
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Fig. 2 Deleterious genomic alterations, genes and tumor sites in Wild‑Type GIST. Matrix demonstrating genes recurrently mutated in WT GIST 
patients, with each column representing an individual patient. VUS missense mutations are displayed only if they are predicted to affect gene func‑
tion by 2 or more algorithms (see “Methods” section). Genes were prioritized on the basis of predicted damaging effect. The table header indicates 
GIST tissue of origin (blue), positive node status (red), positive metastic status (purple), qWT status (i.e. tested for SDHx—black) missing data (grey). 
The number of mutated patients for each gene (red scale in row header) is indicated
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WT GIST are known to be deleterious (K656E, FGFR1-
HOOK3 and FGFR1-TACC1 fusions) in contrast to 
1/5 FGFR1 alterations in the non WT GIST (amplifica-
tion—Additional file  1: Table  S8), thus suggesting that 
the FGFR1 alterations are more likely drivers in the WT 
GIST. PARK2 is a ubiquitin ligase regulating cyclin sta-
bility during G1 to S cell-cycle progression. ATR is a 
subunit of a double-stranded break DNA repair com-
plex. ARID1B is a chromatin remodeling factor that may 
play a role in suppressing the oncogenic Wnt/β-catenin 
pathway [26–30]. SUFU is a negative regulator of Hedge-
hog signaling pathways, which have been implicated 
in directing mesenchymal growth within the GI tract 
and, when overexpressed, in GI tumor carcinogenesis 
[31, 32]. Both ARID1B and SUFU may be actionable via 
FDA-approved histone deacetylase (HDAC) inhibitors 
and Hedgehog pathway inhibitors, respectively. ZNF217 
is a transcription factor associated with poor prognosis 
in various carcinomas, especially increased metastatic 
potential in colorectal cancer [33, 34]. Other recurrently 
mutated genes of interest include APC, BCOR, CDK4, 
MDM2, and TP53 (N =  2 each). Of note, both tumors 
with alterations in BCOR (BCL6 Corepressor) had 
nonsense mutations and were gastric GISTs. BCOR is a 
gene which is implicated in B cell activation and may be 
an example of a link between inflammation and GIST [35, 
36]. Studies of investigational drug RI-BPI, which inhib-
its BCL6 by abrogating its interaction with BCOR, show 
efficacy against diffuse large B-cell lymphomas (DLBCL) 
with BCL6, representing yet another potential targeted 
therapy for specific qWT patients [37, 38]. Moreover, 
by combining EZH2 histone methyltransferase inhibi-
tors with RI-BPI, there have been preliminary reports of 
synergism.
For the first time, we discovered two novel FGFR1 
kinase fusions in GIST, as well as identified a third gene 
fusion that was reported during the preparation of this 
manuscript [39]. These included the aforementioned 
FGFR1–HOOK3 fusion in a 38-year old female with a 
T3N1M1 small bowel GIST and the FGFR1–TACC1 
fusion in a 54-year old male with a T3N1M1 gastric 
GIST, as well as an ETV6–NTRK3 fusion in a 55-year old 
male with a T3N0M1 small bowel GIST (Fig. 3). A total 
of three patients possessed alterations in FGFR1, includ-
ing a 60-year old male with a T3NxM1 small intestine 
GIST with a known FGFR1 missense mutation. Their 
respective FGFR1 alterations were their only known/
likely alterations identified, suggesting a high likeli-
hood of being driver alterations. Of note, an additional 
72-year old male with a T4N1Mx small intestine GIST 
possessed a FGF6 amplification, among multiple other 
GAs, potentially having the same functional impact on 
tumor growth since FGF6 is a reported ligand of FGFR1 
[40, 41].
To increase the possibility of detecting gene fusions 
resulting from intronic breakpoints that would be missed 
with our DNA-based sequencing panel, we investigated 
5 additional cases of qWT GIST collected from an alter-
nate clinical testing laboratory (“Methods” section). 
Table 2 Genes significantly more affected in  wild-type 
GIST
Gene Alterations in non-WT (%) Alterations in WT (%) P value
LTK 2 (1.2 %) 3 (12.5%) 0.01602
SUFU 0 (0 %) 2 (8.3%) 0.01604
ZNF217 0 (0 %) 2 (8.3%) 0.01604
ARID1B 11 (6.8 %) 5 (20.8%) 0.03826
PARK2 1 (0.6 %) 2 (8.3%) 0.04429
ATR 4 (2.5 %) 3 (12.5%) 0.04689
FGFR1 4 (2.5 %) 3 (12.5%) 0.04689
Fig. 3 Kinase fusions identified in WT GIST samples. Three separate fusions involving the N‑terminus of FGFR1 (a) and the C‑terminus of NTRK3 (b) 
were identified. The FGFR1 fusions (a) were similar in structure to reported fusions and contained exons 2‑17 fused with exons 5‑22 of HOOK3 or 
exons 7‑13 of TACC1. Intact coiled‑coil motifs were present in both fusion partners and likely facilitate dimerization. Note that exon 1 of FGFR1 is 
non‑coding and therefore excluded from the protein diagrams. The NTRK3 fusion (b) contained exons 1‑5 of ETV6 and exons 14‑19, which included 
the complete kinase domain. Although the portion of ETV6 present in the fusion lacked the DNA‑binding domain, a Pointed (PNT) was conserved. 
This region is composed of 5‑helix bundle involved in protein–protein interactions and may facilitate dimerization of this fusion. All diagrams are 
drawn to scale
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These included 3 tumors known to express SDHB and 2 
tumors that were without SDH gene mutations but whose 
SDHB protein expression status (as assessed by immu-
nohistochemistry) was unknown. Demographic and 
clinicopathologic data for these 5 patients are provided 
in Additional file 1: Table S9. These cases were addition-
ally analyzed using an RNA-based sequencing panel that 
included primer pairs for 169 known gene fusions that 
involve target genes and 94 fusion partners (Additional 
file  1: Table  S3). We identified one additional case with 
an FGFR1-TACC1 fusion and one additional case with an 
ETV6-NTRK3 gene fusion.
Clinically relevant genomic alterations
At present, many of the identified genomic alterations are 
not clinically actionable or known to be activating genetic 
events. However, alterations in a subset of genes may be 
targetable by off-label use of several FDA-approved or 
investigational targeted therapies. The patient we iden-
tified as having a tumor harboring an ETV6–NTRK3 
fusion was a 55-year old male with T3N0M1 small intes-
tine GIST who was treated with oral LOXO-101 (Loxo 
Oncology, Stamford, CT, USA), the only selective TRK 
inhibitor in clinical development, in a Phase I trial (NCT 
02122913) [42]. The patient was originally diagnosed in 
May 2003 and previously progressed on five lines of ther-
apy, including imatinib (FDA-approved first-line agent 
for GIST), sunitinib (FDA-approved second-line agent 
for GIST, Pfizer), sorafenib (Bayer), nilotinib (Novartis), 
and regorafenib (FDA-approved third-line agent for 
GIST; Bayer). At the time of study entry, the patient had 
significant pain. Upon receiving LOXO-101, the patient 
noted immediate improvement in his symptoms. Tumor 
response to LOXO-101 was seen at the end of week 8 
by PET/CT (Fig.  4). Following 4  months of therapy, the 
patient had an ongoing partial response (44%) accord-
ing to RECIST 1.1 criteria. Of note, this patient’s tumor 
also possessed likely deleterious alterations in PAX5 and 
SETD2. LOXO-101 is now being studied in a worldwide 
Phase II basket trial enrolling patients with solid tumors 
that harbor NTRK1/2/3 fusions (NCT 02576431). It is 
important to note that this symptomatic and radiologic 
response is in stark contrast to the 54-year old male 
with colonic GIST in the secondary study population 
who also possessed an ETV6–NTRK3 fusion. The latter 
patient was heavily pre-treated with progressive disease 
on imatinib (3  months), sunitinib (2  months), sorafenib 
(2  months), and linsitinib (5  months, OSI Pharmaceuti-
cals). The identification of the ETV6–NTRK3 fusion ear-
lier in the disease course may have altered the treatment 
choices and outcome.
Discussion
We report the identification of clinically relevant and 
previously unreported genomic alterations in gastroin-
testinal stromal tumors (GISTs) lacking genomic altera-
tions in KIT, PDGFRA, SDH, and the RAS pathway. We 
profiled patient demographics and tumor characteris-
tics of our cohort and performed CGP of tumors on this 
subset of GIST patients, including reporting of clinical 
responses to molecularly matched therapies. Our find-
ings suggest new and potentially targetable alterations 
in genes such as NTRK3 and FGFR1 in a subset of GIST 
patients.
a b
Fig. 4 Radiological response of a GIST possessing an ETV6–NTRK3 fusion following treatment with LOXO‑101, a selective TRK inhibitor. A 55‑year 
old male with a T3N0M1 small intestine GIST had progression of disease on five lines of tyrosine kinase inhibitors targeting KIT prior to identification 
of an ETV6–NTRK3 fusion in the tumor. He was enrolled on a Phase I clinical trial of oral LOXO‑101 (Loxo Oncology, Stamford, CT), a selective TRK 
inhibitor. As compared to baseline PET/CT images (a), the tumors had decreased size and FDG‑uptake at week 8 (b). At 4 months, the patient had 
ongoing partial response (44%) according to RECIST 1.1 criteria
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The current study focuses on a patient population that 
we are just beginning to understand more thoroughly. 
Even without performing whole exome or whole genome 
sequencing, our study findings expand upon the few 
reports of the molecular characteristics of WT GISTs 
[7, 10, 11, 39, 43]. We compare the incidence of genomic 
alterations in WT and non-WT GIST, yielding seven 
genes that appear to be more commonly altered in WT 
GIST. This includes LTK (lymphocyte receptor tyrosine 
kinase) and FGFR1, two non-KIT/PDGFRA receptor 
tyrosine kinases that mainly signal through the RAS-
MAPK pathway. In addition, LTK also signals through 
the PI3K-AKT-mTOR pathway in order to maintain 
survival signals in tumor cells. These genomic altera-
tions detected in WT GIST affect key pathways such 
as the PI3K-AKT-mTOR and RAS-MAPK pathways, 
which overlap with downstream signaling of several 
known drivers, including KIT and PDGFRA. In addition 
to cell-cycle regulation, other genomic alterations were 
seen to affect histone acetyltransferases, transcriptional 
regulators, and the NFkB pathway, as well as embryonic 
development and cancer stem cell pathways (e.g., Wnt/β-
catenin pathway and Notch pathway). Taken together, 
the genomic profiles highlight novel genes in WT GIST 
with similar or intersecting functions as known drivers of 
non-WT GIST development. Moreover, several of these 
genomic alterations have potential therapeutic impor-
tance. Of note, five mutations in ARID1B, which is part 
of the SWI/SF chromatin remodeling complex, may be 
targetable with FDA-approved HDAC inhibitors, includ-
ing vorinostat and panobinostat. Furthermore, this study 
uncovered mutations in SUFU, a negative regulator of the 
Hedgehog signaling pathway. Because SUFU is down-
stream of the SMO oncogene, FDA-approved agents, 
which target SMO (e.g., vismodegib and sonidegib) are 
unlikely to be effective in tumors with downstream SUFU 
alterations. However, we recently reported that the GLI-
family of transcription factors, which are downstream of 
SUFU, may be targetable in GIST with the FDA-approved 
agent, arsenic trioxide [44]. Thus, our new findings have 
potential therapeutic implications for several subsets of 
WT GIST patients they may be treated with currently 
available drugs or those under development.
We detected an FGF6 mutation and four potentially 
actionable FGFR1 alterations, including one FGFR1 mis-
sense mutation, as well as three FGFR1 fusions including 
a novel FGFR1–HOOK3 fusion and two cases with an 
FGFR1–TACC1 fusion previously reported in glioblas-
toma multiforme. These events are predicted to result in 
constitutive activity of FGFR1 and the downstream tyros-
ine kinase cascades that promote WT oncogenesis per-
haps in the presence or absence of growth factors (e.g., 
FGF6) or FGFR1 overexpression [45, 46]. Thus, a subset 
of GIST, that is similar in size to RAS mutant GISTs in 
the cohort, may be sensitive to targeted FGFR tyrosine 
kinase inhibitors, such as lenvatinib (Esai), ponatinib 
(Ariad), pazopanib (Novartis) or other similar investiga-
tional drugs.
The only prior study defining and comparing genomic 
profiles of 2 qWT GIST to non-qWT GISTs did not 
identify any genomic alterations in the two tumors but 
reported mRNA overexpression of polycomb target 
genes including CDK6, ERG and NTRK2 [11]. Interest-
ingly, we identified genomic alterations in a related gene, 
NTRK3 (fusion with ETV6). ETV6–NTRK3 fusions have 
been reported in infantile fibrosarcoma, secretory breast 
carcinoma, salivary gland tumors (acinic cell carcinomas, 
cystadenocarcinomas, and adenocarcinomas), mixed epi-
thelial and stromal tumor of the kidney, leukemias, and 
thyroid cancer. During the preparation of this manu-
script, another group reported an ETV6–NTRK3 fusion 
in GIST [39]. These findings have clinical relevance as 
recent data (including that shown here) suggest that 
NTRK fusions are sensitive to LOXO-101. Loxo Oncol-
ogy has reported two other NTRK fusion patients with 
clinical responses on its Phase I trial (i.e., sarcoma with 
LMNA–NTRK1 and mammary analogue secretory car-
cinoma of the salivary gland with ETV6–NTRK3) [42]. 
Another report suggests that crizotinib (Pfizer, New 
York, NY, USA) may be a treatment option for patients 
with NTRK fusions [47, 48]. The potential clinical appli-
cability underscores the significant contributions that 
genomic profiling can add towards clinical decision mak-
ing and precision therapies.
The strength of the current study includes the large 
sample cohort and a careful filtering of the mutation 
identified. The genomic data was evaluated through two 
different processes, namely bioinformatic analyses asso-
ciated with the Foundation One™ assays and comparison 
to dbNSFP, in order to identify all potentially relevant 
findings. Foundation Medicine assays include multiple 
gene fusions, which have not been throughly investigated 
by previous studies. This allowed us to identify deleteri-
ous, actionable alteration in FGFR1 and NTRK3 in three 
patients. Foundation Medicine assays however cannot 
distinguish rare germline variants from somatic muta-
tions, leaving some ambiguity in the findings specifically 
in regards to rare germline SDH and NF1 mutations. 
Finally the CGP approach only screened against genes 
with known associations with any solid or hematologic 
cancer, potentially failing to capture truly novel genes 
that have not yet been linked to cancer development.
Given that 12 patients did not have SDHx mutation 
testing, we are unable to definitively determine the pro-
portion of these patients that harbor SDHx mutations or 
are truly WT. Finally, due to the nature of this study, we 
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are unable to match germline and somatic sequencing 
data in patients, repeat testing with the lattest gene panel 
that includes SDHx subunits, perform SDHB immu-
nostaining to assess SDHB-competence/-deficiency, or 
assess for SDHC-epimutant tumors with hypermethyla-
tion of the SDHC promoter, which can lead to silencing 
of expression [7]. Despite the limitations of this study, 
we begin to suggest that 17 qWT GIST are biologically 
distinct from than their non-WT counterparts, providing 
novel insight into the clinico-pathological features of WT 
GIST.
Conclusions
In summary, this study builds upon previous work in 
the GIST field and provides the new insights into the 
genomic landscape of quadruple-WT GIST. While these 
tumors historically are considered “wild-type” mainly 
due to a lack of KIT or PDGFRA mutations, this study 
showed that the majority of these tumors harbor del-
eterious genomic alterations in genes participating in 
crucial cellular activities, such as cell cycle progression, 
DNA repair, and regulation of gene expression. Alter-
natively, it is possible that the activity of the canonical 
genes (i.e., KIT, PDGFRA, KRAS, NF1, BRAF, SDHx, 
KRAS) may also be altered in WT tumors via epige-
netic changes as seen in SDH-deficient tumors. Further-
more, this study identified several actionable mutations, 
including two ETV6–NTRK3 fusions, and FGF6 or 
FGFR1 alterations, including three FGFR1 fusions and 
one known intragenic activating FGFR1 mutation, that 
may significantly impact tumor responses by assisting 
in the choice of targeted therapies. Such findings have 
the potential to change present therapeutic options in 
GIST, give insight into disease biology, and redefine one 
of the earliest paradigms in tumor genomics and preci-
sion medicine. By providing novel insight into potential 
genetic drivers for GIST, future studies may further build 
on this genetic profile of so-called qWT GIST, which are 
not truly WT, as well as link genomic drivers to thera-
peutic regimens. In turn, this may lead to individual-
ized treatments that can significantly improve patient 
outcomes.
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